



**Institutional Biosafety Committee
Meeting Minutes**

The meeting was called to order on 8/26/2025 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance

Voting Members Present:

Hwan Kim
Dafang Wang
Jorge Escobar
Nicholas Carpino
Jeronimo Cello
Christopher Kuhlrow

Non-Voting Attendees, Staff and Guests Present:

Rebecca Dahl
Lu-Ann Kozlowski
Aimee Minton

Recording:

Erin Augello

ITEMS

1. Meeting called to order at 11:30AM

2. Next Meeting Date and General Announcements

The next meeting date is 9/23/2025. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of Minutes from Last Meeting

Review type: Full Committee Review

Action: Approved

Effective date: 8/26/2025

Vote: Total = 6 for = 6 Opposed = 0 Abstained = 0

4. Report on continuing reviews requiring IBC review

This section was reviewed and noted by the committee.

5. Report on New Studies for Committee Review

a. PROTO202500023 How translation speed impacts protein biogenesis

PI:	Jae Ho Lee
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-1

Determination: Approved

Modifications (If Applicable):

- i. In Section: Protocol Team Members
Item 1. Please check "Yes" for all lab staff that are involved with procedures.
- ii. In Section: Funding resources
Item 1. Please provide requested information.
- iii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 1. A brief description of the rsNAM work is all that is required here. Please Condense the response by removing procedural details (e.g., reagents, centrifugation steps, etc.), and instead clearly state what recombinant or synthetic nucleic acids are used, what host/vector systems are involved, and whether any genes are introduced.
- iv. In Section: Risk Group and Containment Practices
Item 2. Physical containment for NIH Guidelines does not need to be BSL-2. Please indicate BSL-1.
- v. Exposure Assessment and Protective Equipment
Although *Saccharomyces cerevisiae* is unlikely to cause disease in healthy human adults it is considered to be an opportunistic pathogen and can in rare cases cause serious infections in immunocompromised individuals. Please acknowledge potential risks involved with working with *S. cerevisiae*, particularly in individuals with severe immunosuppression, prolonged antibiotic therapy, or other compromising factors.

Effective Date: 8/27/2025

Project Expiration: 8/26/2026

Votes:

For:	6
Against:	0
Recused:	0

Absent:	2
Abstained:	0

b. PROTO202500025 Lentiviral Construct Protocol

PI:	Neil Nadkarni
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	• Name: Feldstein Medical Foundation Incorporated, Grant Office ID: , Funding Source ID: • Name: Stony Brook University, Grant Office ID: , Funding Source ID:
Training:	Training is not up to date. Study team member requires ENV001, ENV005. EOS004, ELS003
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. Training is NOT up to date. Nadkarni requires ENV 001, ENV 005. Schappell requires EOS 004, ENV 005. Madeira requires ELS 003, EOS 004, ENV 001, ENV 005.
- ii. In Section: Funding resources
Item 1. Please provide requested information.
- iii. In Section: Bacteria, Yeasts, Fungi, or Parasites
Item 1. Please select BSL-1 conditions for use of E. coli.
Item 2. Explain what "Discuss with Miguel" means, otherwise remove.
- iv. In Section: Biohazards
Item 1. Please select BSL-1 conditions for use of E. coli.
Item 2. Use of PPE does not need to be indicated in this section. Please remove.
- v. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. 3F doesn't apply. Remove.
- vi. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 1. PI only describe the tools to be used for the work, but he does not describe the procedures involving recombinant or synthetic acid molecules. Please state what recombinant or synthetic nucleic acids are used, what host/vector systems are involved, and whether any genes are introduced.

Effective Date: 8/27/2025**Project Expiration:** 8/26/2026**Votes:**

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

6. Report on Amendments Requiring Full IBC Review

a. AMEND202500084 Adding Dr. Chunlian Zhong

PI:	Jun Lin
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

- i. In Section: Primary Cells or Cell Lines
Item 1. PI lists only MDA-MB-231 cells in this section and in the Biohazards section. However, additional cell lines are discussed elsewhere (i.e. T98G, A172, A549, NCI H1688, PC#, C4-2b, etc.), but are not listed in these sections. Please clarify if the work with these additional cells will be conducted now as part of this protocol or at a later date (requiring an amendment). If they are to be used as part of this protocol, please list them.
- ii. In Section: Recombinant or Synthetic Nucleic Acid Work Usage
Item 1. Section III-C does not apply. Use Section III-D.
- iii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 10. Please indicate "Yes" as to whether virus is replication incompetent.
- iv. In Section: Risk Group and Containment Practices
Item 2. Include BSL-2 under subsection "NIH Guidelines rDNA or synthetic nucleic acids."
- v. In Section: Exposure Assessment and Protective Equipment
Item 1. PI description of consequences did not address two key risks of third-generation HIV-based lentiviral vectors: the low but possible generation of replication-competent lentivirus (RCL), and the potential for insertional mutagenesis from integration into host genomes. Please revise to include these points.
- vi. In Section: Waste Management
Item 1. For Point 3, indicate the disinfectant concentration (10% bleach??). Biological waste cannot be poured directly into the drain without having been properly decontaminated.

Effective Date: 8/27/2025

Project Expiration: 8/26/2026

Votes:

For:	6
-------------	---

Against:	0
Recused:	0
Absent:	2
Abstained:	0

7. Review Of Incidents

None

8. Review of Other Agenda Items

None

9. Inspection Results

None

10. Discussion Items/Readings (major and minor points of order)

None

11. Meeting Adjourned at 12:04PM